Pramlintide is an analog of human amylin. Amylin is co-secreted with insulin from pancreatic beta cells and acts centrally to slow gastric emptying, suppress postprandial glucagon secretion, and decrease food intake. These actions complement those of insulin to regulate blood glucose concentrations. Amylin is relatively deficient in patients with type 2 diabetes, depending on the severity of beta-cell secretory failure, and is essentially absent in patients with type 1 diabetes. Through mechanisms similar to those of amylin, pramlintide improves overall glycemic control, reduces postprandial glucose levels, and reduces bodyweight in patients with diabetes using mealtime insulin. SYMLIN® (pramlintide acetate) is indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | SYMLIN Approved UseSYMLIN is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. Launch Date2005 |
Sample Use Guides
•Upon initiation of SYMLIN® (pramlintide acetate), reduce mealtime insulin dose by 50%. Monitor glucoses frequently and individualize subsequent insulin dose adjustments.
•Type 1 Diabetes: Start at 15 mcg subcutaneously before major meals. Increase in 15 mcg increments to a maximum premeal dose of 30 or 60 mcg; if not tolerated, reduce to 30 mcg, as tolerated.
•Type 2 Diabetes: Start at 60 mcg subcutaneously before major meals then increase to 120 mcg before meals, as tolerated.
•Wait at least 3 days between dose titrations to minimize nausea.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29711
Created by
admin on Sat Dec 16 00:24:18 GMT 2023 , Edited by admin on Sat Dec 16 00:24:18 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
356773
Created by
admin on Sat Dec 16 00:24:18 GMT 2023 , Edited by admin on Sat Dec 16 00:24:18 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT000144
Created by
admin on Sat Dec 16 00:24:18 GMT 2023 , Edited by admin on Sat Dec 16 00:24:18 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201669
Created by
admin on Sat Dec 16 00:24:18 GMT 2023 , Edited by admin on Sat Dec 16 00:24:18 GMT 2023
|
PRIMARY | |||
|
SUB12564MIG
Created by
admin on Sat Dec 16 00:24:18 GMT 2023 , Edited by admin on Sat Dec 16 00:24:18 GMT 2023
|
PRIMARY | |||
|
726I6TE06G
Created by
admin on Sat Dec 16 00:24:18 GMT 2023 , Edited by admin on Sat Dec 16 00:24:18 GMT 2023
|
PRIMARY | |||
|
Pramlintide acetate
Created by
admin on Sat Dec 16 00:24:18 GMT 2023 , Edited by admin on Sat Dec 16 00:24:18 GMT 2023
|
PRIMARY | |||
|
C61902
Created by
admin on Sat Dec 16 00:24:18 GMT 2023 , Edited by admin on Sat Dec 16 00:24:18 GMT 2023
|
PRIMARY | |||
|
726I6TE06G
Created by
admin on Sat Dec 16 00:24:18 GMT 2023 , Edited by admin on Sat Dec 16 00:24:18 GMT 2023
|
PRIMARY | |||
|
71306803
Created by
admin on Sat Dec 16 00:24:18 GMT 2023 , Edited by admin on Sat Dec 16 00:24:18 GMT 2023
|
PRIMARY | |||
|
JJ-102
Created by
admin on Sat Dec 16 00:24:18 GMT 2023 , Edited by admin on Sat Dec 16 00:24:18 GMT 2023
|
PRIMARY | |||
|
196078-30-5
Created by
admin on Sat Dec 16 00:24:18 GMT 2023 , Edited by admin on Sat Dec 16 00:24:18 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD